Hiroji Iwata
Expertise in
25
conditions

Hiroji Iwata

Nagoya, JP 
Expertise in
25
conditions
Nagoya, JP 

Overview

Hiroji Iwata practices practicing medicine in Nagoya, Japan.

Iwata is highly rated in 25 conditions, according to our data. Their clinical expertise encompasses Breast Cancer, PIK3CA-Related Overgrowth Spectrum, HER-2 Positive Breast Cancer, Mastectomy, and Hormone Replacement Therapy (HRT).

They are actively involved in clinical research, co-authoring 463 peer reviewed articles and participating in 2 clinical trials.

Locations

Nagoya, Japan
Other Locations
Okazaki, Japan
Toon, Japan
Tokyo, Japan
Chikusa, Japan
Sendai, Japan
Atsugi, 2430034, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized, Open-label Phase III Trial to Evaluate the Efficacy and Safety of Pertuzumab Retreatment in Previously Pertuzumab, Trastuzuamb and Chemotherapy Treated Her2-Positive Metastatic Advanced Breast Cancer
A Randomized, Open-label Phase III Trial to Evaluate the Efficacy and Safety of Pertuzumab Retreatment in Previously Pertuzumab, Trastuzuamb and Chemotherapy Treated Her2-Positive Metastatic Advanced Breast Cancer
Enrollment Status: Completed
Publish Date: September 10, 2025
Intervention Type: Drug
Study Drugs: Trastuzumab, Pertuzumab, Docetaxel, Paclitaxel, Nab-paclitaxel, Vinorelbine, Eribulin, Capecitabine, Gemcitabine
Study Phase: Phase 3
A Phase III Randomized, Double-Blind, Neoadjuvant Study of Hormonal Therapy Plus Palbociclib Versus Hormonal Therapy Plus Placebo in Women With Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer
A Phase III Randomized, Double-Blind, Neoadjuvant Study of Hormonal Therapy Plus Palbociclib Versus Hormonal Therapy Plus Placebo in Women With Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer
Enrollment Status: Completed
Publish Date: March 10, 2023
Intervention Type: Drug
Study Drugs: Palbociclib, Endocrine Therapy
Study Phase: Phase 3
View 1 Less Clinical Trial

462 Total Publications

HER2 Protein Overexpression, mRNA Expression, and DNA Amplification Across Solid Tumors: Comparison of Next-Generation Sequencing-Based Assays With Immunohistochemistry.
HER2 Protein Overexpression, mRNA Expression, and DNA Amplification Across Solid Tumors: Comparison of Next-Generation Sequencing-Based Assays With Immunohistochemistry.
Journal: JCO precision oncology
Published: January 21, 2026

Frequently Asked Questions about Hiroji Iwata

Is Hiroji Iwata a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Hiroji Iwata is classified as an Elite expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Hiroji Iwata participate in research or clinical trials?

Yes. Hiroji Iwata has published 462 articles and abstracts on conditions like Breast Cancer. You can view a list of Hiroji Iwata's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Iwata's expertise for a condition
ConditionClose
View All 18 Advanced Conditions
View All 28 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile